Novo Nordisk (NYSE: NVO) details progress on DKK 15B share repurchase plan

Rhea-AI Filing Summary

Novo Nordisk A/S provides an update on its ongoing share repurchase activity. The company is running a broader share buyback programme of up to DKK 15 billion over a 12-month period beginning 4 February 2026, including a specific programme initiated 6 May 2026 to repurchase B shares for up to DKK 11,200,000,010.45 through 1 February 2027.

As of the latest update, accumulated purchases under the May 2026 programme total 4,000,000 B shares with a transaction value of DKK 1,158,452,492. Novo Nordisk now holds 35,944,480 B shares of DKK 0.10 as treasury shares, equal to 0.8% of its 4,465,000,000 A and B shares outstanding.

Since 4 February 2026, the company has repurchased 18,759,179 B shares at an average price of DKK 264.32 per share, for a total of DKK 4,958,452,482 under the 12‑month programme. The repurchases are conducted under EU Safe Harbour Rules, and detailed daily transaction data is made available on novonordisk.com.

Key Figures

Overall buyback capacity: DKK 15 billion May 2026 sub-programme cap: DKK 11,200,000,010.45 Accumulated under May programme: 4,000,000 B shares +3 more

6 metrics

Overall buyback capacity DKK 15 billion 12-month share repurchase period beginning 4 February 2026

May 2026 sub-programme cap DKK 11,200,000,010.45 B share repurchases from 6 May 2026 to 1 February 2027

Accumulated under May programme 4,000,000 B shares Transaction value DKK 1,158,452,492 as of latest update

Treasury shares held 35,944,480 B shares Treasury position equals 0.8% of share capital

Total shares outstanding 4,465,000,000 shares Total A and B shares, including treasury shares

Shares repurchased since 4 Feb 2026 18,759,179 B shares Average price DKK 264.32; total DKK 4,958,452,482

Key Terms

share repurchase programme, treasury shares, Safe Harbour Rules, foreign private issuer, +1 more

5 terms

share repurchase programme financial

"Novo Nordisk initiated a share repurchase programme in accordance with Article 5"

A share repurchase programme is a company's plan to buy back its own shares from the market. This reduces the total number of shares available, which can increase the value of remaining shares and signal confidence in the company's health. For investors, it can indicate that the company believes its stock is undervalued and may lead to higher share prices.

treasury shares financial

"Novo Nordisk owns a total of 35,944,480 B shares of DKK 0.10 as treasury shares"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

Safe Harbour Rules regulatory

"the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules")"

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

ADRs financial

"Its ADRs are listed on the New York Stock Exchange (NVO)."

American Depositary Receipts (ADRs) are certificates issued by a U.S. bank that stand in for shares of a foreign company, allowing those shares to be bought and sold on U.S. stock exchanges in U.S. dollars. Think of an ADR as a local ticket representing a foreign stock: it makes trading, settlement, and tax reporting simpler for U.S. investors, but still exposes them to risks like currency moves, different accounting rules, and foreign corporate practices.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

June 8, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 8 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 1 June 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	3,130,000		913,270,696
1 June 2026	210,000	292.91	61,512,149
2 June 2026	210,000	280.05	58,810,689
3 June 2026	225,000	276.91	62,305,652
4 June 2026	225,000	278.01	62,553,306
Accumulated under the programme	4,000,000		1,158,452,492

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 35,944,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.8% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12month period beginning 4 February 2026. As of 4 June 2026, Novo Nordisk has since 4 February 2026 repurchased a total 18,759,179 B shares at an average share price of DKK 264.32 per B share equal to a transaction value of DKK 4,958,452,482.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube. 

Contacts for further information

Media:
Ambre James-Brown		Liz Skrbkova (US)
+45 3079 9289		+1 609 917 0632
globalmedia@novonordisk.com		lzsk@novonordisk.com
Investors:
Michael Novod		Jacob Martin Wiborg Rode
+45 3075 6050		+45 3075 5956
nvno@novonordisk.com		jrde@novonordisk.com
Ida Schaap Melvold		Sina Meyer
+45 3077 5649		+45 3079 6656
idmg@novonordisk.com		azey@novonordisk.com
Alex Bruce		Christoffer Sho Togo Tullin
+45 3444 2613		+45 3079 1471
axeu@novonordisk.com		cftu@novonordisk.com
Frederik Taylor Pitter		Mads Berner Bruun
+1 609 613 0568		+45 3075 2936
fptr@novonordisk.com		mbbz@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 37 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: June 8, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer

FAQ

What is Novo Nordisk (NVO) currently authorised to spend on share repurchases?

Novo Nordisk plans to repurchase B shares for up to DKK 15 billion over a 12-month period starting 4 February 2026. This includes a specific May 2026 programme capped at DKK 11,200,000,010.45 under EU Safe Harbour Rules.

How many Novo Nordisk (NVO) B shares have been bought back so far in 2026?

Since 4 February 2026, Novo Nordisk has repurchased 18,759,179 B shares. These were acquired at an average price of DKK 264.32 per share, for a total transaction value of DKK 4,958,452,482 under the ongoing 12-month programme.

What is Novo Nordisk’s (NVO) current treasury share position?

Novo Nordisk now holds 35,944,480 B shares of DKK 0.10 as treasury shares. This represents 0.8% of the company’s total A and B share capital of 4,465,000,000 shares, including treasury holdings.

How much has Novo Nordisk spent under the May 2026 buyback sub-programme?

Under the share repurchase programme initiated on 6 May 2026, Novo Nordisk has accumulated purchases of 4,000,000 B shares. These transactions total DKK 1,158,452,492, with daily volumes and prices disclosed on the company’s website.

Over what period will Novo Nordisk (NVO) execute its current share buyback?

Novo Nordisk’s overall share repurchase programme runs over a 12-month period beginning 4 February 2026. A specific sub-programme started 6 May 2026 is scheduled to continue repurchasing B shares up to 1 February 2027, within defined monetary limits.